SVWAG
NBIX icon

Sound View Wealth Advisors Group’s Neurocrine Biosciences NBIX Stock Holding History

Sound View Wealth Advisors Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$713K Buy
5,414
+171
+3% +$22.7K 0.05% 233
2025
Q4 		$744K Buy
5,243
+27
+0.5% +$3.91K 0.05% 225
2025
Q3 		$732K Buy
5,216
+116
+2% +$15.7K 0.05% 231
2025
Q2 		$641K Buy
5,100
+190
+4% +$21.8K 0.05% 240
2025
Q1 		$543K Sell
4,910
-26
-0.5% -$3.29K 0.04% 244
2024
Q4 		$674K Buy
4,936
+652
+15% +$80.6K 0.05% 228
2024
Q3 		$494K Buy
4,284
+823
+24% +$113K 0.04% 255
2024
Q2 		$476K Sell
3,461
-314
-8% -$43.1K 0.05% 241
2024
Q1 		$521K Sell
3,775
-407
-10% -$55.6K 0.06% 231
2023
Q4 		$551K Sell
4,182
-352
-8% -$40.5K 0.06% 222
2023
Q3 		$510K Buy
4,534
+515
+13% +$54.2K 0.06% 216
2023
Q2 		$379K Buy
4,019
+515
+15% +$50.3K 0.05% 258
2023
Q1 		$355K Sell
3,504
-678
-16% -$70.6K 0.05% 264
2022
Q4 		$551K Buy
4,182
+2,119
+103% +$248K 0.06% 222
2022
Q3 		$219K Buy
+2,063
New +$209K 0.05% 248

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sound View Wealth Advisors Group's NBIX Position: Q1 2026 in Review

Sound View Wealth Advisors Group increased its Neurocrine Biosciences (NBIX) stake by 3.3% in Q1 2026, buying an estimated $22.7K and bringing the position to 5,414 shares worth $713K. The position accounts for 0.05% of the portfolio, ranked #233.

Sound View Wealth Advisors Group first reported a position in NBIX in Q3 2022 and has held it in 15 quarters since. The position peaked at $744K in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Sound View Wealth Advisors Group held 5,414 shares of Neurocrine Biosciences worth $713K as of Q1 2026.
  • Sound View Wealth Advisors Group bought 171 Neurocrine Biosciences shares in Q1 2026, an estimated $22.7K.
  • Neurocrine Biosciences made up 0.05% of Sound View Wealth Advisors Group's portfolio in Q1 2026, its #233 holding.
  • Sound View Wealth Advisors Group first reported a position in Neurocrine Biosciences in Q3 2022 and has held it in 15 quarters since.
  • Sound View Wealth Advisors Group's Neurocrine Biosciences position peaked at $744K in Q4 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Sound View Wealth Advisors Group's 13F filing for Q1 2026, filed 6 May 2026.